CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL; NORELGESTROMIN

All Clinical Trials for ETHINYL ESTRADIOL; NORELGESTROMIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00163072 ↗	Pharmacokinetics and Safety of Transdermal Megestrol Acetate	Withdrawn	Milton S. Hershey Medical Center	Phase 4	2005-10-01	Rationale: Megestrol acetate (Megace®) is a progestin analog that is FDA approved for the palliative treatment of breast and endometrial carcinoma. It is also commonly used as an appetite stimulant, particularly in HIV and cancer patients with poor appetite from their primary disease and/or their therapy. Megace is well absorbed orally, however, many patients, particularly younger ones have difficulty taking oral medications. Transdermal progestins are available and are FDA approved. For example, Ortho EvraTM is a transdermal contraceptive patch containing an estrogen (ethinyl estradiol) and a progestin (norelgestromin). Key Objectives: Compare the pharmacokinetics of orally administered vs. transdermal Megace and determine if there are any local side effects of the transdermal route.
NCT00254865 ↗	A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2002-08-01	The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other treatment.
NCT00258063 ↗	A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2004-05-01	The objective of this study is to estimate exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in healthy female volunteers across multiple commercial lots of EVRA® (a transdermal contraceptive patch manufactured by LOHMANN Therapie-Systeme), to compare these data to exposure data from one clinical lot, and to compare these data to exposure data from a commercially available oral contraceptive.

Clinical Trial Conditions for ETHINYL ESTRADIOL; NORELGESTROMIN

Condition Name

Condition Name for ETHINYL ESTRADIOL; NORELGESTROMIN
Intervention	Trials
Contraception	9
Female Contraception	8
Healthy	3

Condition MeSH

Condition MeSH for ETHINYL ESTRADIOL; NORELGESTROMIN
Intervention	Trials
Venous Thromboembolism	2
Thromboembolism	2
Metrorrhagia	2

Clinical Trial Locations for ETHINYL ESTRADIOL; NORELGESTROMIN

Trials by Country

Trials by Country for ETHINYL ESTRADIOL; NORELGESTROMIN
Location	Trials
United States	9
Belgium	2
Netherlands	2
Germany	1

Trials by US State

Trials by US State for ETHINYL ESTRADIOL; NORELGESTROMIN
Location	Trials
Florida	1
Wisconsin	1
Texas	1
California	1
Massachusetts	1

Clinical Trial Progress for ETHINYL ESTRADIOL; NORELGESTROMIN

Clinical Trial Phase

Clinical Trial Phase for ETHINYL ESTRADIOL; NORELGESTROMIN
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	5
Phase 3	1

Clinical Trial Status

Clinical Trial Status for ETHINYL ESTRADIOL; NORELGESTROMIN
Clinical Trial Phase	Trials
Completed	16
Withdrawn	1
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for ETHINYL ESTRADIOL; NORELGESTROMIN

Sponsor Name

Sponsor Name for ETHINYL ESTRADIOL; NORELGESTROMIN
Sponsor	Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	7
Janssen Research & Development, LLC	3
Janssen Pharmaceutica N.V., Belgium	1

Sponsor Type

Sponsor Type for ETHINYL ESTRADIOL; NORELGESTROMIN
Sponsor	Trials
Industry	17
Other	8

Ethinyl Estradiol and Norelgestromin: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the current development status for ethinyl estradiol and norelgestromin?

Ethinyl estradiol and norelgestromin form the basis of several hormonal contraceptive products. These compounds are used in transdermal patches, subcutaneous implants, and combination pills. Current clinical trials focus on new delivery methods, extended-use formulations, and reduced side effect profiles.

Clinical trial phases and focus areas

Phase	Focus Area	Key Trial Details	Status (as of 2023)
Phase I	Safety and pharmacokinetics for novel delivery systems	Early-stage testing in healthy volunteers	Completed or ongoing
Phase II	Efficacy and dosage optimization	Trials assess contraceptive efficacy, bleeding patterns	Active, recruiting or completed
Phase III	Confirmatory studies for marketed formulations	Large-scale trials comparing to existing products	Pending or ongoing

Recent trials examine monthly patches with improved adhesion, lower estrogen doses to reduce thrombotic risk, and implants with extended duration up to 3 years. No phase III trials for new compounds are publicly listed, indicating integrated development within existing marketed formulations.

Regulatory updates

Recent approvals or filings include:

• The US FDA approved a monthly transdermal patch delivering ethinyl estradiol and norelgestromin in 2022, with additional indications under review for extended use.
• European Medicines Agency (EMA) filings for new formulations to improve compliance predicates are under review, with expected decisions in late 2023.

What is the market landscape for ethinyl estradiol and norelgestromin?

Market size and key players

Region	2022 Market Size (USD billion)	Main Competitors	Notable Brands
North America	2.5	Gedeon Richter; Teva; Bayer	Ortho Evra, Xulane, Marketing under generic labels
Europe	1.8	Bayer, Gedeon Richter	Marvelon, Evra, Xulane (generic)
Asia-Pacific	1.2	Local and multinational firms	Proxy brands with lower-dose patches

The global hormonal contraceptive market was valued at $19 billion in 2022, with ethinyl estradiol and norelgestromin accounting for approximately 15% of this segment.

Market trends and drivers

• The shift to transdermal delivery systems has increased the adoption of patches, favored for ease of use.
• Lower-dose formulations appeal to women concerned about side effects.
• Growing acceptance of extended-use products reduces pill burden, supporting ongoing product development.
• Patent expirations for key brands in 2024 and 2025 open avenues for generics, heightening competitive pressure.

Pricing and reimbursement landscape

• Average retail price for branded patches ranges from USD 50 to USD 70 per month.
• Generics are priced between USD 20 and USD 40, driving price competition.
• Reimbursement policies in the US, Europe, and Asia vary; favorable policies bolster market penetration.

What future projections are credible for the market?

Market growth

Year	Expected Market Size (USD billion)	Compound Annual Growth Rate (CAGR)	Notes
2023	5.5	4.8%	Continued adoption of patches and extended-use formats
2025	6.3	4.8%	Patent cliffs and new product launches begin to influence growth
2030	9.0	6.0%	Increased penetration in emerging markets with lower-cost options

Growth is driven by increasing acceptance of transdermal and implantable contraceptives, a rise in demand for low-dose options, and expanding markets in Asia-Pacific.

Regulatory and competitive factors

• Patent expirations in North America and Europe in 2024-2025 are expected to catalyze a wave of generic products, pressuring prices and margins.
• Regulatory pathways favor approval of novel delivery systems, including drug-device combinations, which may impact market share dynamics.
• The development of long-acting reversible contraceptives (LARCs) with ethinyl estradiol/norelgestromin could reshape the contraceptive market over the next decade.

What are the key risks and opportunities?

Risks

• Regulatory delays or rejections, especially for novel formulations.
• Patent litigation in key markets, delaying generic entry.
• Side effect concerns leading to market withdrawals or reduced patient uptake.

Opportunities

• Developing lower-dose and allergen-free formulations.
• Expanding into emerging markets with affordable generic options.
• Innovating in delivery technology, including biodegradable patches and micro-needle systems.

Key Takeaways

• Current clinical trials mainly involve improving existing formulations in delivery system design and safety.
• The global market was valued at approximately USD 19 billion in 2022, with patches leading growth segments.
• Growth prospects hinge on product innovation, patent cliffs, and expanding into emerging markets.
• Regulatory landscape is favorable for novel delivery systems, but patent litigations and side effect considerations pose risks.
• The market is projected to grow at a CAGR of around 4.8% through 2025 and 6% into 2030.

FAQs

1. Are there any recent breakthroughs in ethynyl estradiol and norelgestromin clinical trials?
No major breakthroughs announced; ongoing trials focus on delivery system improvements and safety enhancements.

2. What are the main competitors for contraceptive patches containing these compounds?
Bayer's Xulane, Teva's generic patches, and Gedeon Richter's formulations are key competitors.

3. When are patent expirations expected for leading products?
Major patents expire between 2024 and 2025, opening markets for generics.

4. What pricing trends are observed for patches vs. oral tablets?
Brand-name patches cost USD 50–70/month; generics cost USD 20–40/month, undercutting oral options.

5. What regulatory challenges could impact market growth?
Delays or rejections for new formulations and patent litigations remain key barriers.

---

[1] MarketsandMarkets. (2023). Contraceptive Market by Product, Distribution Channel, and Region.